TY - JOUR
T1 - Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
AU - Quintas-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Talpaz, Moshe
AU - O'Brien, Susan
AU - Garcia-Manero, Guillermo
AU - Verstovsek, Srdan
AU - Rios, Mary Beth
AU - Hayes, Kimberly
AU - Glassman, Armand
AU - Bekele, B. Nebiyou
AU - Zhou, Xian
AU - Cortes, Jorge
PY - 2005/3/15
Y1 - 2005/3/15
N2 - Deletions of derivative chromosome 9 [der(9)] can be identified by fluorescence in situ hybridization (FISH) in 10% to 15% of patients with chronic myeloid leukemia (CML). Patients with der(9) deletions have been reported to have an adverse outcome when treated with chemotherapy, interferon, and possibly imatinib mesylate. We investigated the frequency and prognostic significance of der(9) deletions among 352 patients with CML treated with imatinib mesylate at our institution, in whom a deletion status of der(9) was determined. Thirty-three patients (9%; 95% CI 0.07, 0.13) (30 in chronic phase, 3 in accelerated phase) had der(9) deletions. The rates of major (82% vs 79%, P = 0.82) and complete cytogenetic response (76% vs 66%, P = .33) with imatinib mesylate therapy were similar in patients with and without der(9) deletions, respectively. After a median follow-up of 28 months, there was no difference in overall survival (P = .30) or response duration (P = .49) in patients with and without deletions. In a multivariate analysis, der(9) deletions had no significant impact on response, survival, or response duration. We conclude that treatment with imatinib mesylate overcomes the adverse prognostic significance of der(9) deletions in patients with CML.
AB - Deletions of derivative chromosome 9 [der(9)] can be identified by fluorescence in situ hybridization (FISH) in 10% to 15% of patients with chronic myeloid leukemia (CML). Patients with der(9) deletions have been reported to have an adverse outcome when treated with chemotherapy, interferon, and possibly imatinib mesylate. We investigated the frequency and prognostic significance of der(9) deletions among 352 patients with CML treated with imatinib mesylate at our institution, in whom a deletion status of der(9) was determined. Thirty-three patients (9%; 95% CI 0.07, 0.13) (30 in chronic phase, 3 in accelerated phase) had der(9) deletions. The rates of major (82% vs 79%, P = 0.82) and complete cytogenetic response (76% vs 66%, P = .33) with imatinib mesylate therapy were similar in patients with and without der(9) deletions, respectively. After a median follow-up of 28 months, there was no difference in overall survival (P = .30) or response duration (P = .49) in patients with and without deletions. In a multivariate analysis, der(9) deletions had no significant impact on response, survival, or response duration. We conclude that treatment with imatinib mesylate overcomes the adverse prognostic significance of der(9) deletions in patients with CML.
UR - http://www.scopus.com/inward/record.url?scp=20144369070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20144369070&partnerID=8YFLogxK
U2 - 10.1182/blood-2004-06-2208
DO - 10.1182/blood-2004-06-2208
M3 - Article
C2 - 15572595
AN - SCOPUS:20144369070
SN - 0006-4971
VL - 105
SP - 2281
EP - 2286
JO - Blood
JF - Blood
IS - 6
ER -